成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >API>Synthetic Anti-infective Drugs>Anti-tuberculous mycobacterium leprae drugs>Thalidomide
Thalidomide
  • Thalidomide
  • Thalidomide

Thalidomide NEW

Price $35 $1.1
Package 1kg 1000kg
Min. Order: 1kg
Supply Ability: g-kg-tons, free sample is available
Update Time: 2024-04-20

Product Details

Product Name: Thalidomide CAS No.: 50-35-1
Min. Order: 1kg Purity: 99%
Supply Ability: g-kg-tons, free sample is available Release date: 2024/04/20
Lead time: In stock, ready for shipment Packaging: bag/bottle/drum/IBC
Delivery: By express, by air, by sea Origin: Manufacturer, advantage product
COA, MSDS: Available, contact us for details Name: Mia

1. Materials information

Names

Name2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione
SynonymMore Synonyms

 Thalidomide Biological Activity

DescriptionThalidomide is initially promoted as a sedative, inhibits ereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ～250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.
Related Catalog
Signaling Pathways >> Metabolic Enzyme/Protease >> E1/E2/E3 Enzyme
Research Areas >> Inflammation/Immunology
Research Areas >> Cancer
Target

Kd: ～250 nM (CRL4CRBN)[1]

In VitroThalidomide is initially promoted as a sedative, has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties, and targets ereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ～250 nM[1]. Thalidomide (50 μg/mL) potentiates the anti-tumor activity of icotinib against the proliferation of both PC9 and A549 cells, and this effect is correlated with apoptosis and cell migration. In addition, Thalidomide and icotinib inhibits the EGFR and VEGF-R2 pathways in PC9 cells[3].
In VivoThalidomide (100 mg/kg, p.o.) inhibits the collagen deposition, down-regulates the mRNA expression level of α-SMA and collagen I, and significantly reduces the pro-inflammatory cytokines in RILF mice. Thalidomide alleviates RILF via suppression of ROS and down-regulation of TGF-β/Smad pathway dependent on Nrf2 status[2]. Thalidomide (200 mg/kg, p.o.) combined with icotinib shows synergistic anti-tumor effects in nude mice bearing PC9 cells, suppressing tumor growth and promoting tumor death[3].
Cell AssayTHP-1 cells, A549 cells and KYSE30 cells are cultured in RPMI-1640 Medium supplemented with 10% fetal bovine serum and maintained at 37?°C in an atmosphere of 5% CO2 and 95% room air. THP-1 cells is irradiated with a single dose of 4?Gy 6-MV X-ray and treated with or without Thalidomide (0.2?μmol/mL)-containing medium for 48?h after radiation. The concentration of Thalidomide is selected based on the preliminary results[2].
Animal AdminMice[2] A total of 24?WT C57BL/6 mice are randomly divided into 4 groups for the experiments (n?=?6 in each group): a control group, an irradiated group, a group irradiated along with Thalidomide, and a Thalidomide only group. Based on the preliminary results, 100 mg/kg Thalidomide is used in the experiment. Thalidomide is dissolved in DMSO vehicle. The treatment group receives the indicated dose of Thalidomide in 200? μL by gavage every other day beginning on day 1 for six treatments. The control mice receives 200 μL 0.1% DMSO contained-saline only. The lungs are harvested at 12 weeks after irradiation for the analysis. A total of 20 Nrf2-/- mice are randomly divided into 4 groups for the experiments (n?=?5 in each group). The experiment procedures of Nrf2-/- mice are the same as WT C57BL/6 mice. In addition, a total of 30?WT C57BL/6 mice are randomly divided into 5 groups for the subsequent experiments (n?=?6 in each group): a control group, an irradiated group, a group irradiated along with CDDO-Me and Thalidomide, a group irradiated along with CDDO-Me, and a group irradiated along with Thalidomide. 600 ng and 100 mg/kg are selected as the dose of CDDO-Me and Thalidomide for the experiment, respectively. The treatment group receives the indicated dose of CDDO-Me or Thalidomide in 200 μL by gavage every other day beginning on day 1 for six times. For the combined group of CDDO-Me and Thalidomide, CDDO-Me is delivered in 200 μL by gavage every other day beginning on day 1 for six treatments. Thalidomide is delivered in 200 ?μL by gavage every other day beginning on day 2 for six treatments[2].
References

[1]. Fischer ES, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014 Aug 7;512(7512):49-53.

[2]. Bian C, et al. Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner. Free Radic Biol Med. 2018 Dec;129:446-453.

[3]. Sun X, et al. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Med Sci Monit. 2018 May 15;24:3193-3203.

 Chemical & Physical Properties

Density1.5±0.1 g/cm3
Boiling Point509.7±43.0 °C at 760 mmHg
Melting Point269-271°C
Molecular FormulaC13H10N2O4
Molecular Weight258.229
Flash Point262.1±28.2 °C
Exact Mass258.064056
PSA83.55000
LogP0.54
Vapour Pressure0.0±1.3 mmHg at 25°C
Index of Refraction1.646
Storage conditionStore at RT
StabilityStable. Combustible. Incompatible with strong oxidizing agents.
Water Solubility45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.6 mg/mL | <0.1 g/100 mL at 22 oC

 MSDS

Thalidomide MSDS(Chinese)

 Toxicological Information

CHEMICAL IDENTIFICATION

  • RTECS NUMBER :

  • TI4375000

  • CHEMICAL NAME :

  • Phthalimide, N-(2,6-dioxo-3-piperidyl)-

  • CAS REGISTRY NUMBER :

  • 50-35-1

  • BEILSTEIN REFERENCE NO. :

  • 0030233

  • LAST UPDATED :

  • 199706

  • DATA ITEMS CITED :

  • 85

  • MOLECULAR FORMULA :

  • C13-H10-N2-O4

  • MOLECULAR WEIGHT :

  • 258.25

  • WISWESSER LINE NOTATION :

  • T56 BVNVJ C- DT6VMVTJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 113 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Administration onto the skin

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 1550 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • >6 gm/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 2 gm/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 800 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • >5 gm/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Mammal - dog

  • DOSE/DURATION :

  • >1538 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rabbit

  • DOSE/DURATION :

  • 21500 mg/kg/43W-I

  • TOXIC EFFECTS :

  • Peripheral Nerve and Sensation - recording from afferent nerve

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 34 gm/kg/57W-I

  • TOXIC EFFECTS :

  • Tumorigenic - equivocal tumorigenic agent by RTECS criteria Tumorigenic - tumors at site of application Lungs, Thorax, or Respiration - tumors

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 2 mg/kg

  • SEX/DURATION :

  • female 30 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 17500 ug/kg

  • SEX/DURATION :

  • female 1-5 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 2 mg/kg

  • SEX/DURATION :

  • female 29 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 16 mg/kg

  • SEX/DURATION :

  • female 28-35 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 560 mg/kg

  • SEX/DURATION :

  • male 14 day(s) pre-mating

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 500 mg/kg

  • SEX/DURATION :

  • female 10-14 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 500 mg/kg

  • SEX/DURATION :

  • female 7-11 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 1050 mg/kg

  • SEX/DURATION :

  • female 1-21 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetal death

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 28 gm/kg

  • SEX/DURATION :

  • male 3 day(s) pre-mating female 3 day(s) pre-mating - 22 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - urogenital system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 200 mg/kg

  • SEX/DURATION :

  • female 15 day(s) pre-mating

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - skin and skin appendages Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 1200 mg/kg

  • SEX/DURATION :

  • female 9-11 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 22 mg/kg

  • SEX/DURATION :

  • female 6-9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • DOSE :

  • 45 mg/kg

  • SEX/DURATION :

  • female 10 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - eye/ear

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • DOSE :

  • 15 mg/kg

  • SEX/DURATION :

  • female 9-14 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • DOSE :

  • 45 mg/kg

  • SEX/DURATION :

  • female 12 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 1700 mg/kg

  • SEX/DURATION :

  • female 6-22 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 750 mg/kg

  • SEX/DURATION :

  • female 2-7 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 600 mg/kg

  • SEX/DURATION :

  • female 1-7 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Newborn - stillbirth

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 400 mg/kg

  • SEX/DURATION :

  • female 12-15 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Maternal Effects - parturition Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 155 mg/kg

  • SEX/DURATION :

  • female 7-11 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 124 mg/kg

  • SEX/DURATION :

  • female 7-10 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - abortion Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 25 mg/kg

  • SEX/DURATION :

  • female 9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 25 mg/kg

  • SEX/DURATION :

  • female 9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 100 mg/kg

  • SEX/DURATION :

  • female 13 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - other effects to embryo

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 2 gm/kg

  • SEX/DURATION :

  • female 11-12 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 390 mg/kg

  • SEX/DURATION :

  • female 8-20 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 2 gm/kg

  • SEX/DURATION :

  • female 20-24 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetal death

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 250 mg/kg

  • SEX/DURATION :

  • female 20-24 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 10 mg/kg

  • SEX/DURATION :

  • female 28 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - eye/ear

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 60 mg/kg

  • SEX/DURATION :

  • female 24-26 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 330 mg/kg

  • SEX/DURATION :

  • female 1-33 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 110 mg/kg

  • SEX/DURATION :

  • female 10-20 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Effects on Embryo or Fetus - fetal death

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 360 mg/kg

  • SEX/DURATION :

  • female 15-17 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - abortion Reproductive - Specific Developmental Abnormalities - homeostasis

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 150 mg/kg

  • SEX/DURATION :

  • female 7 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 450 mg/kg

  • SEX/DURATION :

  • female 7-9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - urogenital system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 450 mg/kg

  • SEX/DURATION :

  • female 7-9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 400 mg/kg

  • SEX/DURATION :

  • female 7-16 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - other developmental abnormalities Reproductive - Effects on Newborn - biochemical and metabolic

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 833 mg/kg

  • SEX/DURATION :

  • female 6-11 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - gastrointestinal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 125 mg/kg

  • SEX/DURATION :

  • female 8-12 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • DOSE :

  • 1500 mg/kg

  • SEX/DURATION :

  • female 6-20 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - other developmental abnormalities Reproductive - Specific Developmental Abnormalities - body wall

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • DOSE :

  • 1700 mg/kg

  • SEX/DURATION :

  • female 1-17 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • DOSE :

  • 1800 mg/kg

  • SEX/DURATION :

  • female 3-20 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • DOSE :

  • 1200 mg/kg

  • SEX/DURATION :

  • female 1-20 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • DOSE :

  • 750 mg/kg

  • SEX/DURATION :

  • female 6-10 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • DOSE :

  • 12500 ug/kg

  • SEX/DURATION :

  • female 8-12 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • DOSE :

  • 10 mg/kg

  • SEX/DURATION :

  • female 7 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 900 mg/kg

  • SEX/DURATION :

  • female 7-12 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - gastrointestinal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 1050 mg/kg

  • SEX/DURATION :

  • female 7-13 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Unreported

  • DOSE :

  • 500 mg/kg

  • SEX/DURATION :

  • female 7 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - Central Nervous System

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 550 mg/kg

  • SEX/DURATION :

  • female 12-33 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 300 mg/kg

  • SEX/DURATION :

  • female 8 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetal death

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 1500 mg/kg

  • SEX/DURATION :

  • female 8-12 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetal death

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 1800 mg/kg

  • SEX/DURATION :

  • female 13-18 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death

  • TYPE OF TEST :

  • Unscheduled DNA synthesis

  • TYPE OF TEST :

  • Mutation test systems - not otherwise specified

MUTATION DATA

  • TEST SYSTEM :

  • Rodent - rat

  • DOSE/DURATION :

  • 7600 mg/kg/30D (Continuous)

  • REFERENCE :

  • NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869- Volume(issue)/page/year: 202,1080,1964 *** REVIEWS *** TOXICOLOGY REVIEW BCSTB5 Biochemical Society Transactions. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1973- Volume(issue)/page/year: 2,695,1974 TOXICOLOGY REVIEW PLMJAP Pahlavi Medical Journal. (Shiraz, Iran) V.1-9, 1970-78. Volume(issue)/page/year: 6,160,1975 TOXICOLOGY REVIEW AUHPAI Australian Journal of Hospital Pharmacy. (B.R. Miller, POB 125, Heidelberg, Vic., Australia) V.1- 1971- Volume(issue)/page/year: 4(1),5,1974 TOXICOLOGY REVIEW CRTXB2 CRC Critical Reviews in Toxicology. (CRC Press, Inc., 2000 Corporate Blvd., NW, Boca Raton, FL 33431) V.1- 1971- Volume(issue)/page/year: 2,365,1973 TOXICOLOGY REVIEW INTEAG Internist. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1960- Volume(issue)/page/year: 15,7,1974 TOXICOLOGY REVIEW CLPTAT Clinical Pharmacology and Therapeutics (St. Louis). (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1960- Volume(issue)/page/year: 5,480,1964 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 TOXICOLOGY REVIEW ATXKA8 Archiv fuer Toxikologie. (Berlin, Fed. Rep. Ger.) V.15-31, 1954-74. For publisher information, see ARTODN. Volume(issue)/page/year: 28,135,1971 TOXICOLOGY REVIEW NEJMAG New England Journal of Medicine. (Massachusetts Medical Soc., 10 Shattuck St., Boston, MA 02115) V.198- 1928- Volume(issue)/page/year: 267,1238,1962 TOXICOLOGY REVIEW NEJMAG New England Journal of Medicine. (Massachusetts Medical Soc., 10 Shattuck St., Boston, MA 02115) V.198- 1928- Volume(issue)/page/year: 267,1184,1962 TOXICOLOGY REVIEW LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,45,1962 TOXICOLOGY REVIEW BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 2,646,1962 TOXICOLOGY REVIEW LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,303,1962

 Safety Information

SymbolArticle illustration Article illustration
GHS07, GHS08
Signal WordDanger
Hazard StatementsH302-H360D
Precautionary StatementsP201-P280-P301 + P312 + P330-P308 + P313
Personal Protective EquipmentEyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
Hazard CodesT:Toxic
Risk PhrasesR46;R61;R21;R25;R62
Safety PhrasesS53-S22-S26-S36/37/39-S45
RIDADRUN 2811 6.1/PG 3
WGK Germany3
RTECSTI4375000
Packaging GroupIII
Hazard Class6.1(b)
HS Code2925190090


2. Packaging of materials

  • For powders: normal is 25kgs/Drum or bag, or larger/smaller package as request.

  • For liquids: normal 25kgs/drum, 180-300kgs/bucket, or IBC, determined by the nature of the product. 

                             Or smaller package 1kg/bottle, 10kgs/bottle as request. 


Article illustrationArticle illustration


3. Shipping & Delivery

  • By Express

Provide door to door service

Suitable for goods under 50kg

Delivery: 3-7 days

Cost: low cost

Article illustration


  • By Air

Provide airport to airport service

Suitable for goods over 50kg

Delivery: 3-14 days

Cost: high cost

Article illustration


  • By Sea

Provide seaport to seaport service

Suitable for goods over 100kg

Delivery: 2-45 days

Cost: low cost

Article illustration


4. Contact information

For more details, pls contact us freely.

Email address: mia@fdachem.com

Mob: 86 18336764634

WhatsApp/Skype/Wechat/LINE: 86 18336764634













Company Profile Introduction

Henan Fengda Chemical Co., Ltd. is located in the High-tech Development Zone of Henan Province. Specializing in the production and sales of various fine chemical products required for industrial production, including chemical raw materials, organic raw materials, petrochemicals, chemical reagents, solvents, catalysts, and additives, etc.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$97.00/500mg
VIP5Y
TargetMol Chemicals Inc.
2024-10-31
$97.00/500mg
VIP3Y
TargetMol Chemicals Inc.
2024-10-31
$10.00/1kg
Henan Bao Enluo International TradeCo.，LTD
 2023-06-26
$690.00/10kilograms
VIP3Y
Hebei Dangtong Import and export Co LTD
 2023-02-17
$0.00/25KG
VIP5Y
Hebei Mojin Biotechnology Co., Ltd
 2022-07-11
$35.00/1kg
Hebei baicao biology science and technology co., ltd
 2022-04-06
$1.00/10g
Guangzhou Biocar Biotechnology Co.,Ltd.
 2022-01-19
$19.00/1Kg/Bag
Hong Kong Tiansheng New Material Trading Co., Ltd
 2022-01-07
$1070.00/1g
Qiuxian Baitai New Material Co., LTD
 2021-11-05
$0.00/25KG
Hangzhou Huarong Pharm Co., Ltd.
 2021-09-16
  • Since: 2023-02-10
  • Address: Room 01, 2288 E05, Building 14, East Henan University, Science and Technology Park, 279 Xisanhuan Ro
INQUIRY